Archives

Archive for November, 2011

hiding uptown

from Google Maps®, Street View So, I was wrong. It happens. In a recent post [in the shadows…], I said this: I assumed that this study was done by Quintiles because Amir Kalali was named as an author. However, the word "Quintiles" doesn’t appear in the on-line data supplement, on clinicaltrials.gov, or in the FDA […]

in the shadows…

After the post about Quintiles [an invisible empire II…], I recalled Amir Kalali’s name from somewhere else – the Latuda [Lurasidone] Trial I was writing about a few months back [ought to know by now…]. Over the Thanksgiving holiday while off visiting, I read it again for signs of Quintiles’ presence. Not much shows in […]

happy thanksgiving…

an invisible empire II…

Back in March, I made an attempt to understand the Clinical Research Organizations: the clinical research industry: time-to-market and beyond… the clinical research industry: the CRCs… the clinical research industry: the cro running in the background… the clinical research industry: cross purposes… the clinical research industry: an invisible empire… the clinical reasearch industry: the ‘atypical’ […]

2006…

Those of you who have been at this a while must giggle at people like me who are new to the scene as we discover things that you’ve known for a long time. I’ve been at this for a while now. I know that because I start looking something up, and find a link to […]

a walk on the wrong side side of the street?…

integrity [ɪnˈtɛɡrɪtɪ]     noun adherence to moral principles; honesty the quality of being unimpaired; soundness unity; wholeness c.1450, "wholeness, perfect condition," from O.Fr. integrité, from L. integritatem [nom. integritas] "soundness, wholeness," from integer "whole" [see integer]. Sense of "uncorrupted virtue" is from 1548. In the last two decades, the Pharmaceutical Industry has been able to opportunize […]

following along

In an earlier post [starting over…], I was commenting on the proposal to include the Attenuated Psychosis Syndrome in the DSM-5. In that post, I reviewed the comments from two members of the DSM-5 Work Group and a letter in response. I missed something. The DSM-5 Work Group had responded to the letter: Response to […]

a competency hearing…

I’ve only included three points from the  American Counseling Association letter below. The whole thing is thoughtful and deserves a read, particularly if you haven’t caught up on the many objections to the DSM-5: Counselor’s Turn Against DSM-5: Can APA Ignore 120,000 Users? Psychiatric Times By Allen Frances, MD November 17, 2011 The users’ revolt […]

so far off track…

I doubt that many think it strange for the American College of Neuropsychopharmacology to have a scientific session called Will We Have New Drugs or Not? Addressing the Crisis in Neuropsychiatric Drug Discovery [page 12]. After all, that’s what Neuropsychopharmacologists think about a lot. And I suppose that having the Director of the NIMH give […]

entrepreneurial neuroscience…

I noticed that the ACNP [American College of Neuropsychopharmacology] meeting was coming up in early December, and I was perusing the program looking for something specific. What were the people identified by Senator Grassley’s investigation up to these days? Were they still active in ACNP? What I found was this session, and it sent me […]